Cargando…

Nanomedicines in the treatment of chronic hepatitis C – focus on pegylated interferon alpha-2a

Nanotechnology is the application of nanotechnology within medicine. An illustration of this is the use of pegylation as a means of modifying naturally occurring proteins which may have clinical applications, in order to improve the pharmacodynamics of the protein resulting in an effective medicatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomas, Thea, Foster, Graham
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2673816/
https://www.ncbi.nlm.nih.gov/pubmed/17722508
_version_ 1782166601982803968
author Thomas, Thea
Foster, Graham
author_facet Thomas, Thea
Foster, Graham
author_sort Thomas, Thea
collection PubMed
description Nanotechnology is the application of nanotechnology within medicine. An illustration of this is the use of pegylation as a means of modifying naturally occurring proteins which may have clinical applications, in order to improve the pharmacodynamics of the protein resulting in an effective medication. An example of this is pegylated interferon. The purpose of this review is to examine the chemistry, clinical pharmacology, pharmacokinetics, pharmacodynamics, and clinical studies with 40 kDa pegylated interferon to illustrate the general principles of pegylated biological proteins. The use in clinical practice is reviewed along with the evidence for both efficiacy, safety, and advantages over standard interferon.
format Text
id pubmed-2673816
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-26738162009-04-30 Nanomedicines in the treatment of chronic hepatitis C – focus on pegylated interferon alpha-2a Thomas, Thea Foster, Graham Int J Nanomedicine Review Nanotechnology is the application of nanotechnology within medicine. An illustration of this is the use of pegylation as a means of modifying naturally occurring proteins which may have clinical applications, in order to improve the pharmacodynamics of the protein resulting in an effective medication. An example of this is pegylated interferon. The purpose of this review is to examine the chemistry, clinical pharmacology, pharmacokinetics, pharmacodynamics, and clinical studies with 40 kDa pegylated interferon to illustrate the general principles of pegylated biological proteins. The use in clinical practice is reviewed along with the evidence for both efficiacy, safety, and advantages over standard interferon. Dove Medical Press 2007-03 2007-03 /pmc/articles/PMC2673816/ /pubmed/17722508 Text en © 2007 Dove Medical Press Limited. All rights reserved
spellingShingle Review
Thomas, Thea
Foster, Graham
Nanomedicines in the treatment of chronic hepatitis C – focus on pegylated interferon alpha-2a
title Nanomedicines in the treatment of chronic hepatitis C – focus on pegylated interferon alpha-2a
title_full Nanomedicines in the treatment of chronic hepatitis C – focus on pegylated interferon alpha-2a
title_fullStr Nanomedicines in the treatment of chronic hepatitis C – focus on pegylated interferon alpha-2a
title_full_unstemmed Nanomedicines in the treatment of chronic hepatitis C – focus on pegylated interferon alpha-2a
title_short Nanomedicines in the treatment of chronic hepatitis C – focus on pegylated interferon alpha-2a
title_sort nanomedicines in the treatment of chronic hepatitis c – focus on pegylated interferon alpha-2a
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2673816/
https://www.ncbi.nlm.nih.gov/pubmed/17722508
work_keys_str_mv AT thomasthea nanomedicinesinthetreatmentofchronichepatitiscfocusonpegylatedinterferonalpha2a
AT fostergraham nanomedicinesinthetreatmentofchronichepatitiscfocusonpegylatedinterferonalpha2a